[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"somatic-symptom-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:somatic-symptom-disorder":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,81,103,133,159,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100431561","phase-2-study-of-dextromethorphan-in-ocd-and-related-disorders-100431561",false,"NCT04899687","Study of Dextromethorphan in OCD and Related Disorders","Fluoxetine\u002FDextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study","Inclusion Criteria:\n\n* Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)\n* Living within California\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Current bipolar disorder or psychotic disorder\n* Active moderate or severe substance use disorder, lifetime severe substance use disorder\n* Pregnant or nursing women\n* Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start\n* Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start","ALL","18 Years","65 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.",[27,28,29,30],"Obsessive-Compulsive Disorder","Illness Anxiety Disorder","Body Dysmorphic Disorders","Somatic Symptom Disorder",[32,33,34,35,36,37],"OCD","BDD","IAD","SSD","Fluoxetine","Dextromethorphan","RECRUITING","2026-05-18",{"date":41,"type":42},"2026-05-20","ACTUAL",{"date":44,"type":42},"2022-01-20",{"date":46,"type":21},"2028-12-01",{"name":48,"class":49},"Stanford University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":50},"100451693","use-repetitive-transcranial-magnetic-stimulation-to-treat-somatic-symptom-disorder-100451693","NCT05161819","Use Repetitive Transcranial Magnetic Stimulation to Treat Somatic Symptom Disorder","Use Repetitive Transcranial Magnetic Stimulation to Treat Somatic Symptom Disorder: A Randomized Double-blind Sham-controlled Crossover Study","Inclusion Criteria:\n\n* Patient with somatic symptom disorder (confirmed by psychiatrists)\n* Age 20-70\n\nExclusion Criteria:\n\n* Having psychotic symptoms or cognitive impairment\n* Having potentially lethal illness\n* Using cardiac pacemakers or defibrillators\n* Currently pregnant or having plans to become pregnant within the next three months\n* Received rTMS treatment within three months\n* Cannot read the questionnaires by oneself\n* Having to take the following medications persistently: bupropion \\>300 mg\u002Fday、TCA、clozapine、chlorpromazine、foscarnet、ganciclovir、ritonavir、theophylline","20 Years","70 Years",{"count":61,"type":21},30,[63],"NA","This is a randomized double-blind sham-controlled crossover study; the interventions are high-frequency rTMS stimulation on left DLPFC and sham control. The study population is the patient with somatic symptom disorder. The primary outcomes are somatic distress and health anxiety.",[30],[67,68,69,70,71],"somatic symptom disorder","repetitive transcranial magnetic stimulation","dorsolateral prefrontal cortex","somatic distress","health anxiety","2026-03-16",{"date":74,"type":42},"2026-03-18",{"date":76,"type":42},"2022-08-29",{"date":78,"type":21},"2026-12-31",{"name":80,"class":49},"National Taiwan University Hospital",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":50},"100500182","developing-an-integrated-psychotherapy-with-cognitive-behavioral-therapy-and-biofeedback-therapy-for-somatic-symptom-disorder-100500182","NCT05792930","Developing an Integrated Psychotherapy With Cognitive-behavioral Therapy and Biofeedback Therapy for Somatic Symptom Disorder","Developing an Integrated Psychotherapy With Cognitive-behavioral Therapy and Biofeedback Therapy for Somatic Symptom Disorder: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patient with somatic symptom disorder (confirmed by psychiatrists)\n\nExclusion Criteria:\n\n* The age is younger than 20 or older than 70 years\n* Having psychotic symptoms or cognitive impairment\n* Having a potentially lethal illness\n* Cannot read the questionnaires by oneself",{"count":20,"type":21},[63],"This research program is aimed to develop a integrative psychotherapy (including CBT and biofeedback therapy) and to examine its efficacy on treatment of somatic symptom disorder. The study design is a randomized controlled trial with waiting list control. Scores of Patient Health Questionniare-15 and Health Anxiety Questionnaire are the primary endpoints.",[30],[67,93,94,70,71],"cognitive behavioral therapy","biofeedback therapy","2025-12-17",{"date":97,"type":42},"2025-12-19",{"date":99,"type":42},"2023-07-11",{"date":101,"type":21},"2026-06-30",{"name":80,"class":49},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100490499","alexithymia-and-attachment-style-in-patients-with-somatic-symptoms-100490499","NCT05666921","Alexithymia and Attachment Style in Patients With Somatic Symptoms","Somatic Symptoms, Alexithymia and Styles of Attachment: a Cross-sectional Study","Inclusion Criteria:\n\n* Clinical condition characterized by somatic symptoms such as recurrent abdominal pain, recurrent vomiting, dyspepsia, psychogenic cough, and chronic functional pain (headache, migraine, musculoskeletal pain) for which an organic cause has been excluded and whose symptom has had a strong impact on the quality of life (presence of the symptom for six months, school absenteeism, social isolation, immobility, psychological distress, difficulty in participating in sports and extracurricular activities, etc.), as per Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria.\n* Age between 11 and 17 years\n* Italian speaking\n* Patients' and parents' consent\n\nExclusion Criteria:\n\n* Cognitive and\u002For developmental impairment\n* Difficulty in understanding the Italian language\n* Presence of organic disease diagnosis\n* Lack of informed consent\n* Patient who does not meet DSM-5 criteria for somatic symptom disorder\n\nCaregiver exclusion criteria:\n\n* Cognitive deficits\n* Difficulty in understanding the Italian language\n* Lack of informed consent\n\nControl group population inclusion criteria:\n\n* Age between 11 and 17 years\n* Adequate knowledge of the Italian language\n* Consent to participate","11 Years","17 Years",{"count":113,"type":21},300,"OBSERVATIONAL","To evaluate whether emotional awareness, attachment style and the ability to abstract and symbolize (IQ) influence the appearance of somatic symptoms. Hypothesis: the investigators expect the presence of somatic symptoms linked to the lower ability of emotional awareness, to lower ability to abstract and symbolize and to an insecure attachment style.",[30],[118,119,120,121,122],"somatic symptoms","alexithymia","attachment style","pain","reflective function","2025-09-24",{"date":125,"type":42},"2025-09-26",{"date":127,"type":42},"2021-06-15",{"date":129,"type":21},"2026-12",{"name":131,"class":49},"Meyer Children's Hospital IRCCS",2,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":50},"100568505","istdp-for-patients-with-treatment-resistance-pps-100568505","NCT06682104","ISTDP for Patients with Treatment Resistance PPS","Individual Intensive Short Term Psychodynamic Psychotherapy for Patients with Treatment Resistance Persistent Physical Symptoms","Inclusion Criteria:\n\n* The participant certifies that they have undergone a medical evaluation for their physical symptoms.\n* The participant rates either moderate distress from physical symptoms on the PHQ-15 form (over 10 points) or significant distress from a single physical symptom (at least 2 points for that symptom).\n* The participant expresses interest in exploring whether emotional factors, such as stress, may contribute to their symptom profile.\n* Any prescribed medications must have been stable for at least 1 month.\n* Participants must meet the criteria for non-response\u002Ftreatment resistance, i.e., no reliable change in PHQ-15.\n\nExclusion Criteria:\n\n* Participants suffer from ongoing substance abuse (alcohol or drugs) or are assessed to have severe mental health issues (psychotic disorders, moderate to high suicide risk, antisocial personality disorder, etc.).\n* Participants are currently prescribed medications that are clearly addictive and sedative in nature (e.g., benzodiazepines).\n* Participants are involved in other psychological treatments focused on physical symptoms. However, other psychological treatments are allowed as long as the supportive therapy does not occur more than once a month.\n* Participants do not have sufficient proficiency in the Swedish language.\n* Somatic symptoms is judged to be need further medically evaluation or treatment.",{"count":141,"type":21},40,[63],"Intensive Short-Term Psychodynamic Psychotherapy (ISTDP) for Treatment-Resistant Persistent Physical Symptoms is a therapeutic approach designed to help patients whose physical symptoms have not responded to traditional medical or psychological treatments. These persistent physical symptoms (PPS) often include conditions such as chronic pain, fatigue, or gastrointestinal issues, where a psychological component may be involved.\n\nISTDP focuses on identifying and addressing unconscious emotional conflicts, which are thought to contribute to or exacerbate physical symptoms. The therapy encourages patients to recognize and express repressed emotions, such as anger, sadness, or fear, which may manifest somatically if left unresolved.\n\nFor patients with treatment-resistant PPS, ISTDP offers a focused, time-limited intervention aimed at breaking the cycle of emotional suppression and physical symptomatology. The method involves intense therapeutic engagement, fostering a direct experience of emotions in a controlled environment. Through this process, patients often gain emotional awareness and experience symptom relief.\n\nResearch on ISTDP in this population suggests that it can effectively reduce the severity of physical symptoms, improve emotional well-being, and enhance overall functioning when other treatments have not yielded significant results.\n\nFor patients with treatment-resistant PPS, ISTDP offers a focused, time-limited intervention aimed at breaking the cycle of emotional suppression and physical symptomatology. The method involves intense therapeutic engagement, fostering a direct experience of emotions in a controlled environment. Through this process, patients often gain emotional awareness and experience symptom relief.\n\nResearch on ISTDP for this population suggests that it can be effective in reducing the severity of physical symptoms, improving emotional well-being, and increasing overall functioning when other treatments have failed to produce significant results.",[30,145,146,147,148],"Persistent Physical Symptoms","Functional Somatic Syndrome","Functional Somatic Disorder","Medically Unexplained Symptoms","NOT_YET_RECRUITING","2024-11-08",{"date":152,"type":42},"2024-11-12",{"date":154,"type":21},"2025-02-01",{"date":156,"type":21},"2025-12-31",{"name":158,"class":49},"Daniel Maroti",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":50},"100564652","telehealth-group-based-emotional-awareness-and-expression-therapy-for-patients-with-persistent-physical-symptoms-a-pilot-study-100564652","NCT06631963","Telehealth Group-based Emotional Awareness and Expression Therapy for Patients With Persistent Physical Symptoms: A Pilot Study","Inclusion Criteria:\n\n* The participant certifies that he or she has undergone a medical evaluation for their physical symptoms (see separate certificate).\n* The participant rates either moderate distress from physical symptoms on the PHQ-15 form (over 10 points) or significant distress from a single physical symptom (at least 2 points for that symptom).\n* The participant expresses interest in exploring whether emotional factors, such as stress, may contribute to their symptom profile.\n* Any prescribed medications must have been stable for at least 1 month.\n\nExclusion Criteria:\n\n* Participants suffer from ongoing substance abuse (alcohol or drugs) or are assessed to have severe mental health issues (psychotic disorders, moderate to high suicide risk, antisocial personality disorder, etc.).\n* Participants are currently prescribed medications that are clearly addictive and sedative in nature (e.g., benzodiazepines).\n* Participants are involved in other psychological treatments focused on physical symptoms. However, other psychological treatments are allowed as long as the supportive therapy does not occur more than once a month.\n* Participants do not have sufficient proficiency in the Swedish language.",{"count":166,"type":21},50,[63],"Delivering Emotional Awareness and Expression Therapy (EAET) through digital or telehealth platforms in a group format offers several key advantages. First, it significantly improves access to care, allowing individuals with persistent physical symptoms (PPS) to receive effective, emotion-focused therapy regardless of their geographic location. Telehealth can also benefit those who face mobility issues or have limited access to specialized care in rural or underserved areas.\n\nGroup-based telehealth EAET promotes social connection among participants, fostering a supportive environment where individuals can share experiences, which may enhance therapeutic outcomes. Additionally, the convenience of remote therapy can reduce barriers to participation, such as time constraints and travel costs, making it easier for patients to commit to treatment.\n\nFinally, the digital format allows for flexible, scalable interventions that can be easily integrated into routine psychiatric care, potentially increasing treatment uptake for individuals who might otherwise avoid in-person therapy due to stigma or logistical challenges.",[170,30,147,146],"Somatic Symptom and Related Disorders","2024-10-07",{"date":173,"type":42},"2024-10-08",{"date":175,"type":21},"2025-01-01",{"date":156,"type":21},{"name":158,"class":49},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":186,"sex":16,"minAge":17,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":50},"100511981","mr-spectroscopy-in-post-covid-condition-prior-to-and-following-a-yoga-breathing-intervention-100511981","NCT05946512","MR-spectroscopy in Post-covid Condition Prior to and Following a Yoga Breathing Intervention","MR Spectroscopy in Well-characterized Individuals With and Without Post COVID Condition Prior to and Following a Yoga Breathing Intervention- an Explorative Randomised Controlled Trial","SpeCY","Inclusion Criteria:\n\n* Inclusion criteria for participants with Post COVID condition\n\n  1. Eligible patients will be recruited at the Respiratory Outpatient Clinic (Medical University Innsbruck, Internal Medicine II) from the PRECISE registry or from other participating clinics at Medical University Innsbruck and via local advertisement.\n  2. Persistent respiratory symptoms for 3 months after infection (mMRC dyspnea score ≥ 1).\n  3. Absence of obstructive or restrictive lung disease or unilateral diaphragmatic paresis.\n  4. Medical history with symptoms compatible with DB as assessed by the physician AND Nijmegen cut-off score of \\>23 or reduced MIP. The last two conditions were chosen to provide a readily accessible and objectifiable entry criterion at the inclusion visit.\n  5. Age \\>= 18 years, \\\u003C 50 years.\n  6. Sufficient knowledge of German language for interaction during Yoga and completion of questionnaires.\n\nInclusion criteria for participants with COPD\n\n1. Eligible patients will be recruited at the Respiratory Outpatient Clinic (Medical University Innsbruck).\n2. A postbronchodilator FEV1\u002FFVC ratio less than 0,7 obtained in functional pulmonary testing is required fo diagnosis of COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) Science Committee, 2022).\n3. Persistent respiratory symptoms for 3 months (mMRC≥ 1).\n4. Absence of unilateral diaphragmatic paresis.\n5. Medical history with symptoms compatible with DB as assessed by the physician AND Nijmegen cut-off score of \\>23 or reduced MIP. The last two conditions were chosen to provide a readily accessible and objectifiable entry criterion at the inclusion visit.\n6. Age \\>= 18 years, \\\u003C 50 years\n7. Sufficient knowledge of German language for interaction during Yoga and completion of questionnaires\n\nInclusion criteria for participants with somatic symptom disorder\n\n1. Eligible patients will be recruited at University Hospital for Psychiatry I and II, Medical University Innsbruck) and via local advertisement.\n2. Screening positive for somatic symptoms disorder with the following scores: SSD-12 ≥ 23, SSS-8 ≥ 9.\n3. Persistent respiratory symptoms for 3 months after infection (mMRC≥ 1).\n4. Absence of obstructive or restrictive lung disease or unilateral diaphragmatic paresis.\n5. Absence of medical history with symptoms compatible with DB as assessed by the physician AND Nijmegen cut-off score of \\>23 or reduced MIP. The last two conditions were chosen to provide a readily accessible and objectifiable entry criterion at the inclusion visit.\n6. Age \\>= 18 years, \\\u003C 50 years.\n7. Sufficient knowledge of German language for interaction during Yoga and completion of questionnaires.\n\nInclusion criteria for healthy participants\n\n1. Eligible participants will be recruited via local advertisement.\n2. Absence of significant active mental or somatic disorders\n3. Absence of persistent respiratory symptoms (mMRC\\\u003C 1).\n4. Absence of obstructive or restrictive lung disease or unilateral diaphragmatic paresis.\n5. Absence of medical history with symptoms compatible with DB as assessed by the physician AND Nijmegen questionnaire and MIP within normal limits..\n6. Age \\>= 18 years, \\\u003C 50 years.\n7. Sufficient knowledge of German language for interaction during Yoga and completion of questionnaires.\n\nExclusion Criteria:\n\n* Exclusion criteria for participants with post COVID condition\n\n  1. Conditions precluding magnetic resonance imaging (MRI) such as metal implants in the body (e.g., pacemakers, surgical devices), phobic anxiety, claustrophobia, or pregnancy.\n  2. Active psychiatric conditions interfering with study participation such as psychosis or acute suicidality.\n  3. Severe fatigue interfering with study participation.\n  4. Previous evidence of structural brain abnormality on the structural MRI scan.\n  5. Significant previous meditation or Yoga experience.\n  6. Patients with known carotid stenosis \\>70% or cardiopulmonary contraindications for tilt table and other cardiovascular autonomic function tests (e.g. Valsalva maneuver, deep breathing, standing test).\n\nExclusion criteria for participants with COPD\n\n1. Conditions precluding magnetic resonance imaging (MRI) such as metal implants in the body (e.g., pacemakers, surgical devices), phobic anxiety, claustrophobia, or pregnancy.\n2. Active psychiatric conditions interfering with study participation such as psychosis or acute suicidality.\n3. Severe fatigue interfering with study participation.\n4. Previous evidence of structural brain abnormality on the structural MRI scan.\n5. Medical history of post COVID condition.\n6. Significant previous meditation or Yoga experience.\n7. Patients with known carotid stenosis \\>70% or cardiopulmonary contraindications for tilt table and other cardiovascular autonomic function tests (e.g. Valsalva maneuver, deep breathing, standing test).\n8. Patients dependent on a long-term oxygen therapy (LTOT )\n\nExclusion criteria for participants with somatic symptom disorder\n\n1. Conditions precluding magnetic resonance imaging (MRI) such as metal implants in the body (e.g., pacemakers, surgical devices), phobic anxiety, claustrophobia, or pregnancy.\n2. Other active psychiatric conditions interfering with study participation such as psychosis or acute suicidality.\n3. Severe fatigue interfering with study participation.\n4. Previous evidence of structural brain abnormality on the structural MRI scan.\n5. Medical history of post COVID condition.\n6. Significant previous meditation or Yoga experience.\n7. Patients with known carotid stenosis \\>70% or cardiopulmonary contraindications for tilt table and other cardiovascular autonomic function tests (e.g. Valsalva maneuver, deep breathing, standing test).\n\nExclusion criteria for healthy participants\n\n1. Conditions precluding magnetic resonance imaging (MRI) such as metal implants in the body (e.g., pacemakers, surgical devices), phobic anxiety, claustrophobia, or pregnancy.\n2. Active psychiatric conditions interfering with study participation such as psychosis or acute suicidality.\n3. Previous evidence of structural brain abnormality on the structural MRI scan.\n4. Medical history of post COVID condition.\n5. Significant previous meditation or Yoga experience.\n6. Patients with known carotid stenosis \\>70% or cardiopulmonary contraindications for tilt table and other cardiovascular autonomic function tests (e.g. Valsalva maneuver, deep breathing, standing test).\n\nlegend: PRECISE = a study conducted with participants with post-COVID-19 condition at the Medical University of Innsbruck; mMRC score = modified medical research council score; DB = dysfunctional breathing; MIP = maximal inspiratory pressure; COPD = chronic obstructive pulmonary disease; FEV1\u002FFVC = forced expiratory volume in one second\u002F forced vital capacity; SSD-12 = Somatic Symptom Disorder - B Criteria Scale; SSS-8 = Somatic Symptom Scale - 8;",true,"50 Years",{"count":189,"type":21},320,[63],"From a clinical perspective, we find that many patients with Post COVID condition suffer from severe and debilitating shortness of breath, while routine pulmonary investigations fail to find the cause of the problems experienced. If dyspnea is associated with palpitations, dizziness or anxiety, patients are commonly diagnosed with \"dysfunctional breathing\". From a psychosomatic perspective, the symptom of dysfunctional breathing can be classified as a \"functional symptom\" under the umbrella term of somatic symptom disorder. Therefore, Yoga interventions with special emphasis on breath-guided relaxation are a promising approach. We aim to investigate the psycho-somatic and somato-psychic pathophysiology on a morphological, psychological, functional and biological basis underlying the symptom of dysfunctional breathing. Furthermore, we plan to investigate the mechanism of Yoga intervention on the mental and somatic symptom burden of participants with Post COVID condition. Then, we aim to compare the impact of Yoga on other groups - healthy individuals, patients with chronic obstructive lung disease (COPD), as well as those with somatic symptom disorder. As a control intervention to Yoga guided breathing exercises a social contact group will be used.",[193,30],"Post COVID-19 Condition",[195,196,197],"Yoga breathing intervention","dysfunctional breathing","MR-Spectroscopy","2023-07-13",{"date":200,"type":42},"2023-07-14",{"date":202,"type":21},"2023-07-24",{"date":204,"type":21},"2027-01-01",{"name":206,"class":49},"Medical University Innsbruck"]